A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread
The purpose of this study is to determine whether a combination of Nivolumab and Daratumumab is safe and effective when treating Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, that have advanced or have spread.
Checked against the public recordLast updated Jul 23, 2021 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Bristol-Myers Squibb
- Interventions being studied
- Biological: Nivolumab; Biological: Daratumumab
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com * Patients with metastatic or advanced solid tumors * Women with histologically or cytologically confirmed triple negative breast carcinoma * Participants with histologically or cytologically confirmed pancreatic adenocarcinoma * Participants with histologically or cytologically confirmed Non Small Cell Lung Cancer (NSCLC) Exclusion Criteria: * Active brain metastases or leptomeningeal metastases. * Any serious or uncontrolled medical disorder * Prior malignancy active within the previous 3 years Other protocol defined inclusion/exclusion criteria could apply
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Pacific Shores Medical GroupLong Beach, California
- University Of ColoradoAurora, Colorado
- Moffitt Cancer CenterTampa, Florida
- University Of MichiganAnn Arbor, Michigan
- Providence Portland Medical CenterPortland, Oregon
- Local InstitutionSt Leonards, New South Wales
- Local InstitutionEdmonton
- Local InstitutionLyon
- Local InstitutionMarseille
- Centre Paul StraussStrasbourg
- Universitaetsklinikum Carl Gustav CarusDresden
- Medizinische Universitaetsklinik FreiburgFreiburg im Breisgau
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jul 23, 2021. Always confirm current availability with the study team.